Thermo Fisher Scientific Inc. $TMO Shares Purchased by King Luther Capital Management Corp

Key Points

• King Luther Capital Management increased its Thermo Fisher Scientific stake by 1.2% in the fourth quarter, bringing its holdings to 688,382 shares valued at about $398.9 million.
• Thermo Fisher posted better-than-expected quarterly results, with earnings of $5.44 per share and revenue of $11.01 billion, both above analyst estimates. Revenue rose 6.2% year over year.
• The company also announced a quarterly dividend of $0.47 per share, payable July 15, and analysts currently have a consensus rating of Moderate Buy with an average price target of $616.10.

King Luther Capital Management Corp lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 688,382 shares of the medical research company's stock after purchasing an additional 8,263 shares during the period. Thermo Fisher Scientific comprises approximately 1.6% of King Luther Capital Management Corp's holdings, making the stock its 14th biggest holding. King Luther Capital Management Corp owned 0.18% of Thermo Fisher Scientific worth $398,883,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in shares of Thermo Fisher Scientific by 88.9% during the third quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company's stock worth $1,309,292,000 after buying an additional 1,270,191 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Thermo Fisher Scientific by 54.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company's stock worth $1,732,422,000 after buying an additional 1,262,967 shares during the period. Franklin Resources Inc. lifted its stake in shares of Thermo Fisher Scientific by 21.0% in the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock valued at $2,874,069,000 after purchasing an additional 1,028,125 shares in the last quarter. Corient Private Wealth LLC lifted its position in Thermo Fisher Scientific by 89.1% during the second quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company's stock valued at $720,576,000 after buying an additional 825,649 shares in the last quarter. Finally, Capital World Investors lifted its holdings in shares of Thermo Fisher Scientific by 7.4% during the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company's stock valued at $4,988,132,000 after acquiring an additional 706,572 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at approximately $63,499,170. This represents a 3.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company's stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Up 0.1%

Shares of TMO stock opened at $448.88 on Wednesday. The stock has a 50-day simple moving average of $479.41 and a 200 day simple moving average of $536.31. The stock has a market capitalization of $166.81 billion, a P/E ratio of 24.68, a P/E/G ratio of 1.98 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business's quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific's payout ratio is presently 10.34%.

Analysts Set New Price Targets

Several research firms recently commented on TMO. UBS Group reissued a "neutral" rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research report on Friday, April 24th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Saturday, May 9th. DZ Bank assumed coverage on Thermo Fisher Scientific in a report on Friday, March 27th. They set a "buy" rating and a $610.00 target price for the company. Finally, Morgan Stanley restated an "overweight" rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $616.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.